Alto Neuroscience, Inc. (ANRO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-01

Key Insights

Alto Neuroscience reported positive topline data from a Phase 2 proof-of-concept study for its lead drug candidate ALTO-101, suggesting potential therapeutic benefits for patients.
The company highlighted advancements in its pipeline, indicating a robust research and development program focused on developing novel therapies for central nervous system disorders.
As an emerging growth company, Alto Neuroscience may benefit from the extended transition period for complying with new or revised financial accounting standards, providing flexibility in its reporting requirements.

Want the newest filings?

This analysis covers the filing from 2026-04-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-16

Alto Neuroscience reported its fiscal year 2025 financial results, highlighting the company's continued growth and development of its pipeline of central nervous system therapies.
The company's cash and cash equivalents position of $150 million suggests it has sufficient funding to advance its clinical programs in the near term.
Investors will be looking for updates on the progress of Alto's lead product candidates, including the timelines for key milestones such as clinical trial readouts and regulatory submissions.

Filed: 2026-03-16

Alto Neuroscience, Inc. has raised approximately $120 million in a private placement of common stock and pre-funded warrants, which will provide additional funding to support the company's operations and development efforts.
The company has agreed to file a registration statement with the SEC within 30 days to register the resale of the shares issued in the private placement, providing liquidity for the investors.
The company has expanded its Board of Directors to seven members, likely to provide additional oversight and guidance as it continues to grow.

Other reports for Alto Neuroscience, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.